Genmab — April 2019
-
on yesterdays PD(L)1 discussion - Another one of Bristol-Myers’ PD-1/CTLA-4 combo studies bites the dust - https://endpts.com/another-one-of-bristol-myers-pd-1-ctla-4-combo-studies-bites-the-dust/
-
Det eneste jeg kan se er at kursen siver..
-
Kære Jan,
Ad 1) Darzalex er fortsat under RTOR programmet
Ad 2) Såfremt det ikke længere var under RTOR programmet ville vi få standard behandling procedure og ville være nødsaget til at melde ud hvilken PDUFA dato vi har fået (dato for senest beslutning om godkendelse)
Håber det besvarede dine spørgsmål. For yderligere investor relaterede spørgsmål er du velkommen til at kontakte mig
Andrew Carlsen
Senior Director, IR
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind